Role of blood cell mitochondria in heart failure
Not Applicable
Completed
- Conditions
- Heart failure
- Registration Number
- JPRN-UMIN000022564
- Lead Sponsor
- Hokkaido University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 83
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with active inflammation 2)Patients with malignant tumor 3)Patients who are receiving steroid or immunosuppressant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mitochondrial respiratory capacity in blood cells
- Secondary Outcome Measures
Name Time Method 1)Mitochondrial oxidative stress originated from blood cells 2)Systemic inflammatory biomarkers 3)Systemic oxidative stress 4)Gene expression and protein synthesis regarding mitochondrial function, mitochondrial biogenesis, morphology, and inflammatory cytokines 5)Mitochondrial density in blood cells 6)Events (all-cause death, cardiac death, all-cause hospitalization, and hospitalization for worsening heart failure)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link blood cell mitochondrial dysfunction to heart failure progression in BLOODMITO-HF study?
How do blood cell mitochondrial biomarkers compare to standard-of-care indicators in predicting heart failure outcomes?
What specific mitochondrial biomarkers in blood cells correlate with heart failure severity or prognosis?
Are there known adverse events associated with mitochondrial-targeted therapies for heart failure?
What compounds or combination therapies target mitochondrial dysfunction in heart failure alongside observational studies like BLOODMITO-HF?